DVS-233 SR
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms
Conditions
Vasomotor Symptoms
Trial Timeline
Dec 1, 2003 โ Apr 1, 2004
NCT ID
NCT00421031About DVS-233 SR
DVS-233 SR is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00421031. Target conditions include Vasomotor Symptoms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092911 | Phase 3 | Completed |
| NCT00075257 | Phase 3 | Completed |
| NCT00090649 | Phase 3 | Completed |
| NCT00063206 | Phase 3 | Completed |
| NCT00072774 | Phase 3 | Completed |
| NCT00073762 | Phase 3 | Completed |
| NCT00242229 | Pre-clinical | Completed |
| NCT00256685 | Phase 3 | Completed |
| NCT00421031 | Phase 3 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms